ENVB
Enveric Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.43
−0.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 153.9K | 200.9K | 337.5K | 408.0K | 435.2K |
| Gross Profit | (153.9K) | (200.9K) | (337.5K) | (408.0K) | (435.2K) |
| Operating Expenses | |||||
| R&D Expense | 2.5M | 2.8M | 2.8M | 7.3M | 8.0M |
| SG&A Expense | 6.1M | 5.8M | 6.5M | 8.8M | 11.5M |
| General & Admin Expense | 4.3M | 5.8M | — | 8.9M | — |
| Selling & Marketing Expense | — | — | — | (64.0K) | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 8.6M | 8.6M | 9.3M | 16.0M | 19.5M |
| Cost and Expenses | 8.7M | 8.8M | 9.6M | 16.4M | 20.0M |
| Operating Income (EBIT) | (8.7M) | (8.8M) | (9.6M) | (16.4M) | (20.0M) |
| Non-Operating | |||||
| Interest Income | 274.00 | — | 219.00 | — | 5.25 |
| Interest Expense | 845.00 | 106.00 | — | 3.7K | 5.2K |
| Net Interest Income | (571.00) | (106.00) | 219.00 | (3.7K) | (5.2K) |
| Other Non-Op Income/Expense | (569.00) | 2.5K | 66.2K | (814.4K) | 4.1K |
| Non-Operating Income (excl Interest) | (276.00) | (2.6K) | (66.2K) | 814.4K | (9.3K) |
| EBT (Pre-Tax Income) | (8.7M) | (8.8M) | (9.6M) | (17.3M) | (20.0M) |
| Income Tax Expense | — | 3.4M | 8.9K | 28.9K | (1.5M) |
| Bottom Line | |||||
| Net Income | (8.7M) | (12.1M) | (9.6M) | (17.3K) | (18.5M) |
| Earnings from Cont. Ops | (8.7M) | (12.1M) | (9.6M) | (17.3M) | (18.5M) |
| Earnings from Discont. Ops | — | — | — | 19.0K | — |
| Bottom Line Net Income | (12.1M) | (12.1M) | (9.6M) | (17.5M) | (18.8M) |
| Per Share | |||||
| Basic EPS | ($16.46) | ($36.24) | ($228.48) | ($97.08) | ($156.00) |
| Diluted EPS | ($16.46) | ($36.24) | ($228.48) | ($97.08) | ($156.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.0M | 334719 | 41908 | 179922 | 173189 |
| Diluted Shares Outstanding | 4.0M | 334719 | 41908 | 179922 | 173189 |
| Profitability Metrics | |||||
| EBITDA | (8.6M) | (8.6M) | (9.2M) | (16.9M) | (19.5M) |
| D&A | 153.9K | 200.9K | 337.5K | 408.0K | 435.2K |
| EBIT | (8.7M) | (8.8M) | (9.6M) | (17.3M) | (20.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026